Citations 1
ADAM trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial of adjuvant avelumab (anti-PD-L1 antibody) in merkel cell carcinoma patients with clinically detected lymph node metastases; NCT03271372.
Chandra, Sunandana , Dakhil, Sumia, Fecher, Leslie A. , Gooley, Ted , Hibbert, Reina, Kelly, Ciara M. , Kiriluk, Samantha M., Nghiem, Paul , Nguyen, Vivian , Pelz, Nichole Real, Poisson, Aubrey A., Price, Katharine A. , Sondak, Vernon K. , Thompson, John A. , Bhatia, Shailender , Brohl, Andrew S. , Brownell, Isaac , Ernstoff, Marc S. , Hanna, Glenn J. , Tykodi, Scott S.
Journal of Clinical Oncology | September 5, 2018 | Volume: 36 | Issue: 15_suppl | Pages: TPS9605-TPS9605
